Jonathan Kaufman, MD, provides an overview of multiple myeloma (MM) and reviews current biomarkers and molecular pathways commonly seen in MM.
Recent Advances in Molecular Biomarkers in Multiple Myeloma
Dr Shaji Kumar explains the role of t(11;14) translocation in patients with multiple myeloma and discusses treatment options for this specific population.
Drs Shaji Kumar and Jonathan Kaufman review the BELLINI trial, as well as provide an overview of other investigational studies of BCL2 inhibitors for the treatment of patients with t(11;14) translocation with relapsed refractory multiple myeloma.
Shaji Kumar, MD, talks about new biomarkers that are being explored in patients with multiple myeloma.
Two experts review strategies and barriers to overcome for biomarker testing in patients with multiple myeloma.
Shaji Kumar, MD and Jonathan Kaufman, MD, discuss unmet needs in the multiple myeloma treatment landscape and share their insights on testing for biomarkers.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5